TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10482696

Group type: EXPERIMENTAL
Intervention: Superselective intra-arterial chemotherapy
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Systemic intravenous chemotherapy
Number of subjects: 386

Group type: COMPARATOR
Intervention: Control
Number of subjects: 386
Study: 8651435

Group type: EXPERIMENTAL
Intervention: Minisston
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Gravistat 125
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Rigevidon
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Anteovin
Number of subjects: 179
Study: 2300106

Group type: EXPERIMENTAL
Intervention: Moderate intensity anticoagulation (prothrombin-time ratio, 1.5; INR, 2.65)
Number of subjects: 258

Group type: COMPARATOR
Intervention: High intensity anticoagulation (prothrombin-time ratio, 2.5; INR, 9)
Number of subjects: 258
Study: 6163166

Group type: EXPERIMENTAL
Intervention: gamma-globulin/histamine complex by subcutaneous injection
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: active treatment (gamma-globulin/histamine complex)
Number of subjects: 138

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 138
Study: 31881879

Group type: EXPERIMENTAL
Intervention: High-energy dose TUS combined with a rehabilitation program
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo TUS combined with a rehabilitation program
Number of subjects: 66
Study: 28195933

Group type: EXPERIMENTAL
Intervention: lotrafilcon A lenses
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: balafilcon A lenses
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: comfilcon A lenses
Number of subjects: 282
Study: 26553690

Group type: EXPERIMENTAL
Intervention: PsA‐TT vaccine
Number of subjects: 0
Study: 24055241

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 4509
Study: 21324450

Group type: EXPERIMENTAL
Intervention: Day 3 embryo transfer
Number of subjects: 240

Group type: COMPARATOR
Intervention: Day 5 embryo transfer
Number of subjects: 240
Study: 19189904

Group type: EXPERIMENTAL
Intervention: Immediate listing for liver transplantation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study: 17426157

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 97
Study: 15290413

Group type: EXPERIMENTAL
Intervention: Warmed hydroxyethyl starch (HES) infused at 37.1 degrees +/‐ 1.5 degrees C
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (room temperature HES) infused at 34.8 degrees +/‐ 2.2 degrees C
Number of subjects: 20
Study: 11738336

Group type: EXPERIMENTAL
Intervention: 5-day course of levofloxacin 500 mg once daily
Number of subjects: 532

Group type: COMPARATOR
Intervention: 7-day course of levofloxacin 500 mg once daily
Number of subjects: 532
Study: 9463638

Group type: EXPERIMENTAL
Intervention: Losartan (selective AT1 receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin II
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium depletion
Number of subjects: 0
Study: 8505747

Group type: EXPERIMENTAL
Intervention: Acetard 300 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Acetard 100 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Platet 100 mg
Number of subjects: 45
Study: 3691010

Group type: EXPERIMENTAL
Intervention: Two 5‐mg tablets (Treatment A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One 10‐mg tablet (Treatment B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mL of a 1‐mg/mL suspension (Treatment C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 mL of a 1‐mg/mL aqueous reference solution (Treatment D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison between Treatment A and Treatment D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall mean elimination half‐life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bioequivalence of dosage forms
Number of subjects: 0
Study: 30955362

Group type: EXPERIMENTAL
Intervention: Pedometer worn on the hip with visible step count and daily recording
Number of subjects: 78

Group type: COMPARATOR
Intervention: Pedometer fixed shut worn on the hip with estimated distances recorded
Number of subjects: 78
Study: 28820322

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin (PRF)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Open Flap Debridement (OFD)
Number of subjects: 13
Study: 26159207

Group type: EXPERIMENTAL
Intervention: Osteotome technique
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional drilling technique
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 23926679

Group type: EXPERIMENTAL
Intervention: Spermatic cord seal-up injection (lidocaine, gentamicin or Amikacin, dexamethasone), qd or bid, for 2 courses of 5 days each, with an interval of 3 to 5 days.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group treatment (intravenous drip of penicillin, qd; intramuscular injection of Streptomycin, bid; oral SMZCo, bid, with initial dose doubled).
Number of subjects: 120
Study: 21757663

Group type: EXPERIMENTAL
Intervention: DHA
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: EPA
Number of subjects: 608

Group type: COMPARATOR
Intervention: Japanese population
Number of subjects: 608

Group type: COMPARATOR
Intervention: Multivariable-adjusted IMT
Number of subjects: 608
Study: 19688352

Group type: EXPERIMENTAL
Intervention: NuCore Injectable Nucleus hydrogel
Number of subjects: 14
Study: 16430322

Group type: EXPERIMENTAL
Intervention: Coping intervention
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Academic counseling
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Positive perception of family's finances
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Less emotional distress
Number of subjects: 181
Study: 15387802

Group type: EXPERIMENTAL
Intervention: Eccentric exercises
Number of subjects: 44

Group type: COMPARATOR
Intervention: Night splint
Number of subjects: 44

Group type: COMPARATOR
Intervention: Combination of eccentric exercises and night splint
Number of subjects: 44
Study: 11212044

Group type: EXPERIMENTAL
Intervention: Remifentanil iv followed by a continuous infusion of 0.25 to 0.50 microg x kg(‐1) x min(‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nitroprusside iv
Number of subjects: 30

Group type: COMPARATOR
Intervention: Esmolol iv combined with alfentanil iv
Number of subjects: 30
Study: 9771298

Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms kg‐1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hydroxyzine (1 mg kg‐1)
Number of subjects: 28
Study: 8314135

Group type: EXPERIMENTAL
Intervention: LLETZ
Number of subjects: 375

Group type: COMPARATOR
Intervention: Laser ablation
Number of subjects: 375
Study: 3353831

Group type: EXPERIMENTAL
Intervention: Pneumatic compression stocking applied to the left limb
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (right leg and upper limb without compression)
Number of subjects: 26
Study: 30370613

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Escitalopram plus bupropion SR
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR plus mirtazapine
Number of subjects: 665

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 665
Study: 28235621

Group type: EXPERIMENTAL
Intervention: Low-dose CAP (2 mg/d; L-CAP, n = 27)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High-dose CAP (4 mg/d; H-CAP, n = 22)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (corn starch; PLA, n = 28)
Number of subjects: 77
Study: 25963985

Group type: EXPERIMENTAL
Intervention: 4 g GSR‐PAS twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8 g GSR‐PAS once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NAT1∗14 and NAT1∗3 alleles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NAT1∗10 allele
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NAT1 and NAT2 genotypes
Number of subjects: 0
Study: 23433101

Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg with reduced-dose cyclosporine
Number of subjects: 721

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 3 g/day with standard-dose cyclosporine
Number of subjects: 721
Study: 21615449

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) treatment for 15 months
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) treatment in mice with EAE
Number of subjects: 8

Group type: COMPARATOR
Intervention: Untreated controls (mice)
Number of subjects: 8
Study: 19062230

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol and ipratropium with warmed humidified oxygen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nebulized albuterol and ipratropium with humidified oxygen at room temperature
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nebulized albuterol with warmed humidified oxygen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nebulized albuterol with humidified oxygen at room temperature
Number of subjects: 60
Study: 16684985

Group type: EXPERIMENTAL
Intervention: Collaborative care management (n = 84)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Augmented usual care (n = 69)
Number of subjects: 153
Study: 14762410

Group type: EXPERIMENTAL
Intervention: CRT display for grading of diabetic retinopathy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: TFT display for grading of diabetic retinopathy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CRT display with compression
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: TFT display with compression
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: TFT display for grading of uncompressed images magnified to four times
Number of subjects: 49

Group type: COMPARATOR
Intervention: CRT display
Number of subjects: 49
Study: 11713130

Group type: EXPERIMENTAL
Intervention: Syndrome X patients (n=40)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Coronary artery disease patients (n=53)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control subjects (n=10)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Overall CCS comparison
Number of subjects: 103
Study: 9385910

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 134

Group type: COMPARATOR
Intervention: Isradipine
Number of subjects: 134
Study: 7946899

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 micrograms/d for 8 weeks)
Number of subjects: 0
Study: 3416079

Group type: EXPERIMENTAL
Intervention: Filtered (leukocyte-poor) blood products
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard (control) blood products
Number of subjects: 112
Study: 31810021

Group type: EXPERIMENTAL
Intervention: Nursing-sensitive adverse events
Number of subjects: 1998

Group type: EXPERIMENTAL
Intervention: Preventability of adverse events
Number of subjects: 1998

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of nursing-sensitive adverse events
Number of subjects: 1998

Group type: EXPERIMENTAL
Intervention: Types of nursing-sensitive adverse events
Number of subjects: 1998

Group type: EXPERIMENTAL
Intervention: Gender differences in adverse events
Number of subjects: 1998

Group type: EXPERIMENTAL
Intervention: Admission type differences in adverse events
Number of subjects: 1998

Group type: EXPERIMENTAL
Intervention: Severity of adverse events
Number of subjects: 1998

Group type: EXPERIMENTAL
Intervention: Impact on hospital stay
Number of subjects: 1998
Study: 29229305

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU weekly for 12-14 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Routine protocol (control group)
Number of subjects: 48
Study: 28853392

Group type: EXPERIMENTAL
Intervention: Sertraline prescribed in therapeutic doses for 12 months
Number of subjects: 7

Group type: COMPARATOR
Intervention: High-intensity Cognitive Behavioural Therapy (CBT) delivered in 14 sessions
Number of subjects: 7
Study: 26222482

Group type: EXPERIMENTAL
Intervention: Annual multimodal screening
Number of subjects: 21733

Group type: EXPERIMENTAL
Intervention: Ultrasound screening (US)
Number of subjects: 21733

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 21733
Study: 23571176

Group type: EXPERIMENTAL
Intervention: HPV‐16/18 AS04‐adjuvated vaccine
Number of subjects: 271
Study: 21349542

Group type: EXPERIMENTAL
Intervention: Infants with HLHS born at term (≥37 weeks gestation)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Infants with HLHS from low-poverty areas
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Overall HLHS cases
Number of subjects: 406

Group type: COMPARATOR
Intervention: Control subjects (n=4060)
Number of subjects: 406
Study: 18339153

Group type: EXPERIMENTAL
Intervention: 2 mg/ml of both morphine and ketamine (Ketamine group, n=26)
Number of subjects: 56

Group type: COMPARATOR
Intervention: 2 mg/ml of morphine (Control group, n=30)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ketamine group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 23221287

Group type: EXPERIMENTAL
Intervention: Freshplace intervention
Number of subjects: 233

Group type: COMPARATOR
Intervention: Traditional food pantry control
Number of subjects: 233
Study: 16362788

Group type: EXPERIMENTAL
Intervention: Proton therapy (68-MeV protons)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Stereotactic radiotherapy (SRT) with 6-MV photons
Number of subjects: 10
Study: 12637791

Group type: EXPERIMENTAL
Intervention: sH group
Number of subjects: 95

Group type: COMPARATOR
Intervention: H group
Number of subjects: 95

Group type: COMPARATOR
Intervention: C group
Number of subjects: 95
Study: 10434822

Group type: EXPERIMENTAL
Intervention: Clonidine 2.5 micrograms kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midazolam 300 micrograms kg‐1
Number of subjects: 20
Study: 7559293

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 10 mg bid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 20 mg bid
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2191769

Group type: EXPERIMENTAL
Intervention: Postoperative serum carcinoembryonic antigen (CEA) levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Preoperative serum CEA levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CEA-positive rates
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Survival rates
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Serial postoperative assay of serum CEA levels
Number of subjects: 30
Study: 419163

Group type: EXPERIMENTAL
Intervention: Psychotropic drugs (20 different types)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebos (5 total)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebos from various studies not used for the establishment of the classification rule (9 total)
Number of subjects: 75
Study: 12166685

Group type: EXPERIMENTAL
Intervention: EchoScreen (Madsen Electronics/Fischer‐Zoth GmbH)
Number of subjects: 4248

Group type: COMPARATOR
Intervention: ILO Otodynamics Ltd system
Number of subjects: 4248
Study: 29396712

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CogT)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Waiting time effects
Number of subjects: 77
Study: 27209164

Group type: EXPERIMENTAL
Intervention: Erlotinib plus Bevacizumab (150 mg daily of erlotinib and 15 mg/kg of bevacizumab intravenously on day 1 of every 21-day cycle)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Erlotinib plus Bevacizumab
Number of subjects: 200
Study: 24039147

Group type: EXPERIMENTAL
Intervention: Instant pure soluble coffee (three increasing doses)
Number of subjects: 0
Study: 22449552

Group type: EXPERIMENTAL
Intervention: Ice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no anesthetic)
Number of subjects: 30
Study: 20619460

Group type: EXPERIMENTAL
Intervention: Topical prostaglandin analog (PGA) in 1 eye
Number of subjects: 206
Study: 18928908

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Protein-rich balanced nutrient beverage (control)
Number of subjects: 0
Study: 16352884

Group type: EXPERIMENTAL
Intervention: 1,450-ppm F toothpaste
Number of subjects: 1268

Group type: COMPARATOR
Intervention: 440-ppm F toothpaste
Number of subjects: 1268
Study: 12809961

Group type: EXPERIMENTAL
Intervention: Tramadol 37.5 mg/APAP 325 mg combination tablets
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 11075306

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8866038

Group type: EXPERIMENTAL
Intervention: Zenith Laboratories nicardipine (30 mg) under fasted conditions
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Zenith Laboratories nicardipine under fed conditions
Number of subjects: 34
Study: 1346793

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Albuterol (200 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6396114

Group type: EXPERIMENTAL
Intervention: Bifonazole 1% powder
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bifonazole placebo
Number of subjects: 200
Study: 31727154

Group type: EXPERIMENTAL
Intervention: mDCs vaccination
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of mDCs and pDCs vaccination
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All DC vaccines
Number of subjects: 21
Study: 28914187

Group type: EXPERIMENTAL
Intervention: Externally facilitated program (StrokeLink) using outreach workshops incorporating clinical performance feedback, patient outcomes (survival, quality of life at 90‐180 days), local barrier assessments to best practice care, action planning, and ongoing support.
Number of subjects: 843

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 843
Study: 26876425

Group type: EXPERIMENTAL
Intervention: Programme to Improve Well‐being (PIW) in addition to Cardiac Rehabilitation Programme (CRP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cardiac Rehabilitation Programme (CRP)
Number of subjects: 108
Study: 25044072

Group type: EXPERIMENTAL
Intervention: Nurse-based strategy (home visits and telephone reinforcement)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Conventional strategy (medical follow-up)
Number of subjects: 252
Study: 22413452

Group type: EXPERIMENTAL
Intervention: Landiolol 125 microg x kg(‐1) x min(‐1) for one minute followed by 40 microg x kg(‐1) x min(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not receiving landiolol)
Number of subjects: 20
Study: 20186140

Group type: EXPERIMENTAL
Intervention: Chocolate mousse
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cottage cheese
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chocolate mousse and cottage cheese
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chocolate mousse vs. cottage cheese
Number of subjects: 50
Study: 17664516

Group type: EXPERIMENTAL
Intervention: Collaborative care for depression
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1801
Study: 16084433

Group type: EXPERIMENTAL
Intervention: New synchrony (S) and entropy (E) parameters derived from equilibrium radionuclide angiography
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: SD of ventricular phase (SD Ø)
Number of subjects: 22
Study: 12454559

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 10466236

Group type: EXPERIMENTAL
Intervention: Surgical excision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reoperation or mastectomy
Number of subjects: 0
Study: 7588499

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) replacement therapy for 3 months
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) replacement therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: GHD patients (baseline)
Number of subjects: 25
Study: 2317672

Group type: COMPARATOR
Intervention: Marlex mesh posterior rectopexy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sigmoidectomy combined with sutured posterior rectopexy
Number of subjects: 29
Study: 6990875

Group type: EXPERIMENTAL
Intervention: Inhaled powder of fenoterol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Aerosol administration of fenoterol
Number of subjects: 13
Study: 30986513

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (scaling and root planing) during the first 6 months
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (later intervention group)
Number of subjects: 74
Study: 28371936

Group type: EXPERIMENTAL
Intervention: Task-specific training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Global stretching, memory exercises, and health education sessions
Number of subjects: 0
Study: 26728453

Group type: EXPERIMENTAL
Intervention: Active video gaming (AVG)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Waiting-list (control)
Number of subjects: 13
Study: 24508533

Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (OROS-mph)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 22605570

Group type: EXPERIMENTAL
Intervention: Sulindac (150 mg twice a day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 20537140

Group type: EXPERIMENTAL
Intervention: Self-reported medication side effects
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Risk factors for medication side effects
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Liver problems and doctor's awareness of medications
Number of subjects: 1000